TLR4 Antagonist Patent for Multiple Myeloma Treatment EP3558323A1

Thu, 16 Apr 2026 08:37:38 +0000
Intellectual Property

The European Patent Office granted patent EP3558323A1 for specific TLR4 antagonists in the treatment of multiple myeloma. The patent applicants include Etablissement Français du Sang, CNRS, Université Paul Sabatier Toulouse III, and INSERM. Designated states cover all EU member states plus other EPC contracting states.